Oncotarget

Corrections:

Correction: LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma

Gabriella Cunha Vieira, S. Chockalingam, Zsombor Melegh, Alexander Greenhough, Sally Malik, Marianna Szemes, Ji Hyun Park, Abderrahmane Kaidi, Li Zhou, Daniel Catchpoole, Rhys Morgan, David O. Bates, Peter J. Gabb and Karim Malik _

PDF  |  How to cite

Oncotarget. 2017; 8:32381-32381. https://doi.org/10.18632/oncotarget.17685

Metrics: PDF 1107 views  |   ?  

Present: The originally supplied Figure 5 contains duplicate total-ERK panels.

Corrected: The proper Figure 5 appears below. The authors sincerely apologize for this error.

Original article: Oncotarget. 2015; 6:40053-67. DOI: 10.18632/oncotarget.5548.

Figure 5: LGR5 regulates MEK/ERK and Akt signalling. Immunoblotting demonstrating A. decreases in p-ERK1/2 (T202/Y204) and p-MEK1/2 (S217/221), B. Elevated Bim-EL and C. altered Akt phosphorylation and Rictor levels accompanying LGR5 knockdown.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17685